Symptomatic

patients diagnosed in childhood tend to have more severe disease manifestations [5], and are expected to experience an overall greater burden of disease [6] and [7]. selleck chemical Enzyme replacement therapy (ERT) is recommended for patients, including children, with GD who manifest signs and symptoms [6], [7] and [8]. Early intervention with ERT in symptomatic children may prevent the development of irreversible pathology [6], [7] and [8]. Treatment is also important to improve growth and reduce the impact of the disease on physical and psychosocial development [6], [7] and [8]. Taliglucerase alfa is an ERT that is approved in the United States, Israel, Brazil, Chile, Australia, Canada, and other countries for the treatment of Type 1 GD in adults, for treatment of pediatric patients in AZD0530 concentration the United States, Australia, and Canada, and for hematologic manifestations in pediatric patients with Type 3 GD in Canada. It is the first approved plant cell–expressed recombinant therapeutic protein [9]. Production in a plant cell culture system conveys potential advantages, such as the inability to be contaminated with or propagate mammalian pathogens, along with a potential lower cost [9], [10], [11] and [12]. In the taliglucerase alfa clinical development program, the phase 1 study

was conducted in 6 healthy adult volunteers [13]. Taliglucerase alfa safety and efficacy were then investigated in the phase 3, first-time-in-GD patients, pivotal, 9-month, double-blind, randomized, parallel-group trial in treatment-naïve adult patients [14]. Although it was not pre-specified in the trial

design, all 29 patients completing the study had Type 1 GD. Treatment with taliglucerase alfa 30 U/kg Idoxuridine and 60 U/kg (per infusion every other week) was associated with significant reductions in spleen volume, the primary end point, from baseline to 9 months. Secondary end points included significant reductions in liver volume and significant increases in hemoglobin concentrations and platelet counts from baseline to 9 months. Treatment was generally well tolerated and all drug-related adverse events (AEs) were mild/moderate and transient. The objective of this study was to assess the efficacy and safety of taliglucerase alfa in pediatric patients with GD at the same doses of 30 U/kg and 60 U/kg per infusion every other week as with the pivotal phase 3 trial in adult patients. This study was a phase 3B multicenter, randomized, double-blind, 2-dose trial of taliglucerase alfa (30 U/kg and 60 U/kg per infusion every other week) in pediatric patients (aged 2 to < 18 years). The trial was conducted at 3 centers (Shaare Zedek Medical Center, Jerusalem, Israel; Instituto Privado de Hematologia e Investigacion Clinica [I.P.H.I.C.], Asuncion, Paraguay; and the Morningside Medi-Clinic Johannesburg, South Africa).